The effects of a novel, non-ischemic and pain-free exercise intervention in peripheral artery disease - PROJECT SUMMARY/ABSTRACT
Objective. Our objective is to build on our preliminary work that a Non-IsChemic Exercise (NICE) program
will be a better treatment for patients with peripheral artery disease (PAD) to improve ambulation, health-related
quality of life (HRQoL), microvascular function, and systemic vascular biomarkers than a Standard painful
exercise program.
Specific Aims. We propose to test our central hypothesis that the NICE intervention performed without
inducing leg ischemia and its’ damaging sequela will be a superior exercise paradigm to increase peak walking
time and HRQoL more than the Standard ischemic and painful exercise paradigm via greater improvement in
microvascular mechanisms. This clinically relevant hypothesis will be tested through the following aims:
Aim 1 (Exercise Outcomes) To compare the changes in ambulation and HRQoL in PAD patients
randomized to either the NICE slow walking program or to the Standard program of ischemic and painful exercise.
Aim 2a (Vascular Outcomes) To compare the changes in local microvascular function of the lower
extremities, inflammation and oxidative stress in patients following the NICE program, and following the Standard
ischemic and painful program.
Aim 2b (Exploratory Aim) To explore whether the changes in local microvascular function and systemic
vascular biomarkers are associated with the changes in peak walking time following the NICE and Standard
programs, and whether the association is stronger following the NICE program.
Methods. This is a 3-month, patient-oriented, translational, comparative effectiveness randomized
controlled trial. One-hundred patients will be randomized into either the NICE program (N=50) or the Standard
exercise program (N=50). All patients will perform supervised treadmill walking for 3 months. Patients randomized
to the NICE program will walk intermittently at a slow speed of approximately 1.4 mph for only 2-3 minute bouts
that do not elicit claudication pain. Patients randomized to the Standard program will walk intermittently at a
speed of approximately two mph to near maximal claudication pain.
Clinical Significance. If successful, the NICE program which consists of slow-paced walking that does
not elicit leg ischemia or pain will be a novel and innovative exercise program, and will be the exercise paradigm
of choice to optimally improve peak walking time, HRQoL, local microvascular function, inflammation, and oxidative
stress in PAD patients. These improvements could impact the clinical course of PAD by leading to healthier and
more active lifestyles.